The Latest in CLL

New agents effectively target CLL’s molecular Achilles

December 18, 2015

CLL

Anti-BCL2, CD20 combo safe, effective in untreated CLL

December 17, 2015

CLL

FDA gives nod to rapid-infusion bendamustine for CLL

December 9, 2015

CLL

ASH: Idelalisib plus standard therapy boosts survival in relapsed CLL

December 9, 2015

CLL

Upfront idelalisib carries high risk for acute liver toxicity

December 8, 2015

CLL

ASH: First-line ibrutinib beats standard chemo for CLL/SLL in older patients

December 7, 2015

CLL

ASH: Donor CAR-T cells elicit responses in mixture of progressive B-cell cancers

December 5, 2015

CLL

Medical Roundtable: The Changing Pharmacologic Treatment Landscape in Chronic Lymphocytic Leukemia

October 20, 2015

Five epigenetic biomarkers define three CLL subgroups

October 13, 2015

CLL

IgA increase linked to fewer infections in CLL patients on ibrutinib

October 8, 2015

CLL

MHM: Novel agents, combos show promise for relapsed/refractory CLL

October 2, 2015

CLL

MHM: Novel agents, combos show promise for relapsed/refractory CLL

October 2, 2015

CLL

CLL Therapy: Focus on comorbidities, not age

October 1, 2015

CLL

CLL: No symptoms, no treatment still appropriate

September 30, 2015

CLL

HELIOS trial: Ibrutinib safely boosts survival in CLL/SLL

September 21, 2015

CLL